Cargando…
Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal canc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110705/ https://www.ncbi.nlm.nih.gov/pubmed/35063062 http://dx.doi.org/10.3727/096504022X16427607626672 |
_version_ | 1784709159297482752 |
---|---|
author | Liu, Shuai Lu, Lu Pan, Feng Yang, Chunsheng Liang, Jing Liu, Jinfeng Wang, Jian Shen, Rong Xin, Fu-Ze Zhang, Nan |
author_facet | Liu, Shuai Lu, Lu Pan, Feng Yang, Chunsheng Liang, Jing Liu, Jinfeng Wang, Jian Shen, Rong Xin, Fu-Ze Zhang, Nan |
author_sort | Liu, Shuai |
collection | PubMed |
description | Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the Kaplan–Meier method. The efficacy and safety of fruquintinib were also assessed. Seventy-five patients were involved in our study, and 29.3% of patients achieved stable disease (SD). Median PFS was 5.4 months (95% CI: 4.841–5.959). The treatment-emergent adverse events (TEAEs) with fruquintinib were acceptable with grade 3 TEAEs of 6%. The grade 3 TEAEs were hand–foot skin reaction (HFSR), fatigue, and stomatitis. The ECOG performance status was associated with PFS. In this real-world study, the clinical activity of fruquintinib was consistent with what has been reported in previous clinical trials. The level of safety was acceptable, and the side effects were manageable. |
format | Online Article Text |
id | pubmed-9110705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cognizant Communication Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-91107052022-06-14 Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer Liu, Shuai Lu, Lu Pan, Feng Yang, Chunsheng Liang, Jing Liu, Jinfeng Wang, Jian Shen, Rong Xin, Fu-Ze Zhang, Nan Oncol Res Article Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the Kaplan–Meier method. The efficacy and safety of fruquintinib were also assessed. Seventy-five patients were involved in our study, and 29.3% of patients achieved stable disease (SD). Median PFS was 5.4 months (95% CI: 4.841–5.959). The treatment-emergent adverse events (TEAEs) with fruquintinib were acceptable with grade 3 TEAEs of 6%. The grade 3 TEAEs were hand–foot skin reaction (HFSR), fatigue, and stomatitis. The ECOG performance status was associated with PFS. In this real-world study, the clinical activity of fruquintinib was consistent with what has been reported in previous clinical trials. The level of safety was acceptable, and the side effects were manageable. Cognizant Communication Corporation 2022-05-04 /pmc/articles/PMC9110705/ /pubmed/35063062 http://dx.doi.org/10.3727/096504022X16427607626672 Text en Copyright © 2022 Cognizant, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License. |
spellingShingle | Article Liu, Shuai Lu, Lu Pan, Feng Yang, Chunsheng Liang, Jing Liu, Jinfeng Wang, Jian Shen, Rong Xin, Fu-Ze Zhang, Nan Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer |
title | Real-World Data: Fruquintinib in Treating Metastatic Colorectal
Cancer |
title_full | Real-World Data: Fruquintinib in Treating Metastatic Colorectal
Cancer |
title_fullStr | Real-World Data: Fruquintinib in Treating Metastatic Colorectal
Cancer |
title_full_unstemmed | Real-World Data: Fruquintinib in Treating Metastatic Colorectal
Cancer |
title_short | Real-World Data: Fruquintinib in Treating Metastatic Colorectal
Cancer |
title_sort | real-world data: fruquintinib in treating metastatic colorectal
cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110705/ https://www.ncbi.nlm.nih.gov/pubmed/35063062 http://dx.doi.org/10.3727/096504022X16427607626672 |
work_keys_str_mv | AT liushuai realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT lulu realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT panfeng realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT yangchunsheng realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT liangjing realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT liujinfeng realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT wangjian realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT shenrong realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT xinfuze realworlddatafruquintinibintreatingmetastaticcolorectalcancer AT zhangnan realworlddatafruquintinibintreatingmetastaticcolorectalcancer |